Abstract
Purpose:
Granular corneal dystrophy type 2 (GCD2) is caused by a point mutation (R124H) in the TGF-β–induced gene (TGFBI). However, the mechanisms underlying the accumulation of TGF-β–induced protein (TGFBIp) are poorly understood. Therefore, we evaluated the signaling cascade affecting the expression of TGFBIp using patient-derived cells.
Methods:
Keratocyte primary cultures were prepared from corneas from the eye bank or from heterozygous or homozygous patients with GCD2 after penetrating or lamellar keratoplasty. GCD2 diagnoses were based on the results of a DNA analysis for the R124H TGFβI mutation. Keratocytes were treated with various cytokines and then analyzed using quantitative PCR (qPCR) array, qPCR, flow cytometry, ELISA, and Western blotting.
Results:
TGFBI expression was counterregulated by IL-7 in corneal fibroblasts. IL-7 expression was significantly reduced in corneal fibroblasts from patients with GCD2. TGF-β and TGFBI expression were reduced on IL-7 treatment in corneal fibroblasts. Interestingly, the interplay between TGF-β and IL-7 was regulated by the RANKL/RANK signaling cascade. Also, IL-7 regulates the expression of a membrane-type matrix metalloproteinase (MT-MMP), which plays a crucial role in migration and neovascularization in the cornea.
Conclusions:
These studies demonstrate that impaired IL-7 expression in patients with GCD2 affects disease pathogenesis via a failure to control TGF-β expression. The RANKL/RANK axis regulates TGF-β and TGFBI expression via IL-7–mediated MT-MMP regulation in corneal fibroblasts. These findings improve our understanding of the pathogenesis of GCD2.
Granular corneal dystrophy type 2 (GCD2) is an autosomal-dominant type stromal dystrophy caused by a point mutation (R124H) in the TGF-β–induced gene (
TGFBI) on chromosome 5q31.
1 Typically, small white irregularly shaped deposits attributed to the accumulation of the TGF-β–induced protein (TGFBIp) are found in the corneal stroma, resulting in the disruption of corneal transparency and eventually a loss of vision.
2,3 Studies of GCD2 have established the importance of a
TGFBI mutation in the pathogenesis; however, the mechanisms underlying the accumulation of TGFBIp and its clearance are poorly understood. In the steady state, most TGFBIp, also known as kerato-epithelin, is produced by the corneal epithelium. During the process of wound healing in the normal human cornea, TGFBIp is found in both the epithelium and keratocytes near the site of the wound, suggesting that keratocytes produce TGFBIp.
4,5 The mechanism by which wild-type (WT) or mutant (MUT) TGFBIp is degraded is highly complicated and many unresolved issues remain, including the cell types that are functional, the types of proteases that play important roles, and how amyloidogenesis occurs in a single mutated peptide.
6,7 Another interesting point is that the cornea is the only tissue affected by this disease. Other organs (or tissues) show no clear functional or morphological abnormalities during the whole life span of humans, despite universal expression of the MUT form of
TGFBIp.
IL-7 was initially identified as a factor required for the growth of murine B-cell precursors
8; however, subsequent studies have shown that IL-7 plays an important role in T cells, dendritic cells, and fibroblasts.
9–11 The role of IL-7 in rheumatoid arthritis (RA) has been studied owing to its elevated levels in the serum of patients with RA and its increased expression in the RA synovium, synovial fibroblasts, and chondrocytes.
11,12 IL-7 is now known to be produced by many types of fibroblasts, not only in immune tissues, such as the thymus, bone marrow, and lymph nodes, but also in nonimmune tissues, like the skin,
13,14 intestine,
15 and liver.
15 With respect to eye diseases, IL-7 has been found in the pseudophakic vitreous
16 and tear fluids
17 from thyroid ophthalmopathy.
18 Interestingly, IL-7 inhibits fibroblast TGF-β production and tissue fibrosis.
19,20 Thus, it is possible that IL-7 contributes to the pathogenesis of GCD2 by affecting TGF-β and subsequent TGFBIp expression in corneal fibroblasts (i.e., keratocytes). Despite the relatively high level of TGF-β expression in ocular tissues, especially the cornea, which maintains immune privilege, to the best of our knowledge, the relationship between corneal fibroblasts and IL-7 expression has not been evaluated in any corneal pathologies.
In this study, we evaluated the expression and regulation of IL-7 and its corresponding receptors in the cornea as well as their functional roles in TGF-β–mediated TGFBIp accumulation and clearance in a GCD type 2 disease model using immortalized human corneal fibroblasts from healthy subjects and patients with GCD type 2.
An FITC-conjugated mouse anti-human CD127 (IL-7Ra) antibody was obtained from BioLegend (San Diego, CA, USA). The PE-conjugated mouse anti-human/mouse CD265 (RANK) antibody was obtained from Thermo Fisher (Rockford, IL, USA). Human TGF-β1 ELISA Duo Set and Human TGFBIp ELISA Duo Set were obtained from R&D Systems (Minneapolis, MN, USA). Human RANKL (receptor activator of nuclear factor kappa B ligand) was donated by Eun Ju Chang, PhD (Asan Bio Institute, Seoul, Korea). Human IL-7, human TGF-β1, and human TGFβI protein were obtained from R&D Systems.
Isolation of Corneal Fibroblasts From Healthy and Granular Dystrophy Type 2 Patients
Culture of Corneal Fibroblasts From Healthy Subjects and Patients With Granular Corneal Dystrophy Type 2
Cell surface antigens were analyzed by flow cytometry. The cells were incubated with anti-human CD127 (IL-7Rα)-APC (Catalog No. 351316, clone A019D5, isotype, mouse IgG1; BioLegend) or anti-human CD265 (RANK)-PE antibody (Catalog No. FAB683P, Clone #80704, isotype, mouse IgG1; R&D Systems) for 30 minutes at 4°C. The cells were then washed twice with 0.5% BSA-PBS and analyzed using the FACS CANTO II (Becton Dickinson, San Jose, CA, USA).
Lentiviral particles containing small hairpin RNA (shRNA) targeting human IL-7 (sc39629-V), IL-7Rα (sc-35664-V), or control shRNA lentiviral particles (sc-108080) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Keratocytes were cultured in a 24-well plate (1 × 105 cells/well) and infected with each lentiviral particle according to the manufacturer's protocol. Control keratocytes generated using control shRNA lentiviral particles, IL-7 knockdown (KD) keratocytes generated using IL-7 shRNA lentiviral particles (IL-7KD keratocytes), and IL-7Rα KD keratocytes generated using IL-7Rα shRNA lentiviral particles (IL-7RαKD keratocytes) were cultured in puromycin-containing (4 to 6 μg/mL) medium for 2 weeks to select stable clones. Puromycin-resistant colonies were picked. The expression of IL-7 was examined with an anti-IL-7 antibody by Western blotting and the expression of IL-7Rα was examined with an anti-IL-7Rα-APC antibody by FACS.
Keratocytes were lysed in lysis buffer containing 150 mM NaCl, 20 mM Tris-HCl, pH 7.5, 10 mM EDTA, 1% Triton X-100, 1% deoxycholate, 1.5% aprotinin, and 1 mM phenylmethylsulfonyl fluoride. Cellular debris was removed by centrifugation. Cell lysates were resolved by SDS-PAGE and electroblotted onto polyvinylidene difluoride membranes. After blocking with 5% skim milk in TBS-T (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.05% Tween 20), the membranes were probed with antibodies. For Western blotting, anti-TGFBI and anti-GAPDH antibodies were used. The proteins were detected using the Enhanced Chemiluminescence System (Thermo Scientific, Waltham, MA, USA).
The generation of graphs and statistical analyses were performed using GraphPad Prism (GraphPad, La Jolla, CA, USA) or Microsoft Excel 2010 (Microsoft, Redmond, WA, USA). Results are expressed as means ± SEM. Statistical comparisons between groups were performed using independent t-tests, and P values were adjusted by Bonferroni correction. P < 0.05 was considered statistically significant.
Basal Expression Levels of IL-7, IL-7R, TGF-β1, and TGFβI in WT and MUT Keratocytes
Despite extensive studies, the exact proteolytic enzymes, such as MMPs, for TGFBIp remain unidentified. However, our previous results suggest that proteolytic enzymes associated with extracellular matrix (ECM) turnover may be involved in TGFBIp deposition in GCD2.
29 In addition, Akhtar et al.
30 reported that altered ECM proteolytic enzyme activities affect TGFBIp deposition by degrading ECM molecules, either by the scission of covalent bonds or the cleavage of MUT TGFBIp. Korvatska et al.
3 suggested that abnormal proteolysis is involved in the deposition of TGFBIp in the cornea in cases of corneal dystrophy. Accordingly, we previously investigated the expression patterns of collagen metabolism-related MMP-1 and -2, the prominent MMPs in corneal tissues. However, we found higher levels of MMP-1 and -2 in heterozygous and homozygous GCD2 than in WT keratocytes, suggesting that MMP-1 and -2 are not critical for the degradation on TGFBIp. Surprisingly, we found that MMP14, a membrane-type MMP, rather than secretory MMPs, was significantly reduced in GCD2 keratocytes.
MT-MMPs, including MMP14 (MT1-MMP), are able to directly degrade various ECM components, including collagens, gelatin, fibronectin, vitronectin, and laminin, and directly activate other MMPs.
31–34 Accordingly, many studies have shown that the loss of MT-MMPs leads to a significant disturbance of connective tissue metabolism.
31,33 We also found that MT-MMP mRNAs are more highly expressed in the cornea, the target location for TGFBIp accumulation in disease development, than in other tissues (e.g., the liver or muscle) (data not shown). These results also imply that MT-MMPs have more important roles in the homeostasis of corneal matrix proteins than in other organs or tissues. Therefore, the elevated TGF-β activity with decreased MMP14 in GCD2 may facilitate the accumulation of ECM proteins in the cornea, including TGFBIp, and this might be the core mechanism underlying TGFBIp accumulation in GCD2 corneas. In addition to MMP14, we found that MMP15 and MMP16 were also reduced in CF and important for the degradation of TGFBIp. All three MT-MMPs, MMP14, 15, and 16, were reduced in CF from patients with GCD2. In addition, IL-7 stimulates MMP13 expression via the activation of the receptor for advanced glycation end products (RAGE) in chondrocytes.
12 Therefore, IL-7 may play an important role in the expression of TM-MMPs, not only in corneal tissues, but also in tissues where ECM accumulates.
Another interesting finding of this study is that the RANKL/RANK axis is an upstream pathway for the activation of IL-7R signaling, inhibition of TGF-β, and TM-MMP expression to maintain ECM homeostasis in the cornea. RANKL/RANK is an important signaling pathway in osteoclasts, which functions in the absorption of the bone tissue. In addition to osteoclastogenic activity, extensive investigations have revealed that the RANKL/RANK axis has key regulatory functions in bone homeostasis, organogenesis, immune tolerance, and cancer metastasis.
22 In the eye, RANKL, OPG, and RANK were detected, and these factors were upregulated in corneal stromal cells by epithelial injury
35; however, no studies have evaluated RANKL expression levels and ocular pathology. We found that RANKL is a key regulator of TM-MMP expression and ECM remodeling by reducing TGFBIp via IL-7 activation in keratocytes using a GCD2 model. Interestingly, GCD2 keratocytes expressed significantly reduced levels of RANK, thereby reducing IL-7 activation as well as MMP14 expression. Interestingly, as described previously, the RANKL/RANK axis is key element in osteoclasts and could directly induce osteoclastogenesis, which requires high MMP levels to break down bone tissues. Consistent with these findings and the results of Wilson et al.,
35 RANKL/RANK-activated keratocytes share similar characteristics with those of osteoclasts that produce MMPs and play an essential role in the breakdown of ECM proteins, including TGFBIp. Therefore, it is quite reasonable that GCD2 cells, which exhibit reduced RANK and IL-7 activity, show TGFBIp accumulation; eventually, the cornea turns opaque and patients lose their vision.
This study had several limitations. First, we were unable to perform in vivo or human studies. Recently, Yamazoe et al.
36 reported a transgenic mouse model with the R124H mutation of human TGFBIp and found corneal opacities. Despite differences between mice and humans, this mouse model may be useful for verifying the results of our study. Second, we could not provide indirect evidence for MMP14-mediated TGFBIp digestion. As MMP14 is an MT-MMP, we could not measure proteolytic activity for TGFBIp in vitro. To maintain the biological activity of MMP14, we used an MMP14 inhibitor to measure the breakdown of TGFBIp using in vitro keratocyte culture. The full-length MMP14 peptide, which shows sufficient biological activity, may resolve the issue of MMP14-mediated TGFBIp digestion.
In conclusion, keratocytes expressed RANKL/RANK as well as IL-7R, similar to immune cells. These findings suggest that keratocytes are not simple fibroblasts, but a type of immune cell with multifunctional roles in the maintenance of homeostasis in the cornea. In addition, we identified the MMP subtypes involved in the degradation of TGFBIp (i.e., TM-MMP, and not secretory-type MMPs). These results provide a basis for studies of the breakdown of other amyloid or hyaline-form proteins that accumulate in various diseases affecting the brain, kidney, and other major organs.
Supported by Science Research Program Grant No. NRF-2018R1A2B3001110 and Grant No. NRF-2017M3A7B4041798 through the National Research Foundation of Korea.
Disclosure: S.Y. Kim, None; A. Yeo, None; H. Noh, None; Y.W. Ji, None; J.S. Song, None; H.C. Kim, None; L.K. Kim, None; H.K. Lee, None